PTC Therapeutics Announces Initiation of a Registration-Directed Clinical Trial to Evaluate Vatiquinone in Mitochondrial Epilepsy

Print Friendly, PDF & Email

– Global Phase 2/3 trial now enrolling patients with highly morbid unmet medical condition – SOUTH PLAINFIELD, NJ, USA I October 26, 2020 I PTC Therapeutics, Inc. (NASDAQ: PTCT ), today announced the initiation of a registration-directed Phase 2/3 clinical trial to evaluate vatiquinone (PTC743) in patients with mitochondrial […]